• October 2010: ViThera wins a Silver Prize (Runner-Up) at MassChallenge Download the press release.
  • August 2010: ViThera featured in Xconomy Boston. Ryan McBride, correspondent for Xconomy, covers ViThera's mission of generating novel therapeutics in an interview with ViThera's founder Johannes Fruehauf. Read more.
  • 2010: ViThera reaches final round in MassChallenge, the world's largest global startup competition. The competition was designed to accelerate the development and success of high-growth, high-impact new businesses, while stimulating job creation across the Commonwealth and beyond. ViThera joins other finalists for the accelerator phase of the competition.Download a list of the teams.
  • May 2010: Special Symposium on Therapeutic use of Engineered Bacteria. ViThera’s President, Johannes Fruehauf, will chair the Special Symposium on the Therapeutic use of Engineered Bacteria during the 110th General Meeting of the American Society of Microbiology, May 23-27 San Diego, CA. The symposium is designed to highlight the various novel technologies that are being developed in the field, ranging from vaccine use to RNAi and therapeutic peptide delivery. The panel of invited speakers from industry and academia includes Jay Keasling, Philippe Langella, Catherine Grillot-Courvalin and Dirk Brockstedt. The panel will discuss recent progress in the development of live bacterial therapeutics based on Coli, Lactic acid bacteria, Listeria from the bench towards clinical applications.
  • January 2010: ViThera Laboratories exits virtual mode and starts operations at One Kendall Square in Cambridge. ViThera Labs was founded by Johannes Fruehauf, former Head of R&D at Cequent Pharmaceuticals, and Professor Philippe Langella of the Institut National de Recherche Agronomique (INRA) in Paris, France. ViThera is assembling a dedicated team of scientists and business professionals to create a novel class of drugs based on the innovative use of beneficial and probiotic bacteria. ViThera also offers custom laboratory and consulting services to biotechnology companies in Cambridge.